NICE technology appraisal guidance TA875 supports the use of semaglutide 2.4 mg (Wegovy) for adults who meet specific criteria: BMI 35 kg/m with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, or obstructive sleep apnoea) BMI 3034.9 kg/m in certain higher-risk groups For people from certain ethnic backgrounds including South Asian, Chinese, other Asian, Middle Eastern, Black African, and African-Caribbean groups lower BMI thresholds apply (typically approximately 2.5 kg/m lower than standard thresholds), in line with NHS and NICE guidance on ethnicity-related metabolic risk Treatment must be delivered as part of a specialist weight management service providing multidisciplinary support Treatment duration under TA875 is limited to a maximum of 2 years Should retatrutide receive regulatory approval and a positive NICE appraisal, it is likely that similar eligibility criteria would apply, potentially with additional considerations given its more potent mechanism of action
Ash was kind and informative and he made the whole experience very comfortable
From the air we breathe to the water we drink, environmental pollutants have become unwelcome companions in our daily lives
Through regular follow-up appointments, either in-person or virtually, we will closely monitor your progress and make any necessary adjustments to your treatment plan
The Science Behind Semaglutide-Related Hair Loss Semaglutide and hair loss share a complex connection that involves several biological mechanisms
Manjishtha Capsules The standardized extract of the widely-known Manjishtha herb (Rubia cordifolia) is used for preparing these capsules
